Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials

1995, Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group, BMJ, 311, 899, 10.1136/bmj.311.7010.899

Pfister, 2004, American society of clinical oncology treatment of unresectable non-small cell lung cancer guideline: update 2003, J Clin Oncol, 22, 330, 10.1200/JCO.2004.09.053

D’Addario, 2005, Platinum-based versus non-platinum-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis of the published literature, J Clin Oncol, 23, 2926, 10.1200/JCO.2005.03.045

Pujol, 2006, Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials, Lung Cancer, 51, 335, 10.1016/j.lungcan.2005.11.001

Fossella, 2003, Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group, J Clin Oncol, 21, 3016, 10.1200/JCO.2003.12.046

Rosell, 2002, Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small cell lung cancer: a cooperative multinational trial, Ann Oncol, 13, 1539, 10.1093/annonc/mdf332

Schiller, 2002, Comparison of four chemotherapy regimens for advanced non-small cell lung cancer, N Engl J Med, 346, 92, 10.1056/NEJMoa011954

Jelic, 2001, Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study, Lung Cancer, 34, 1, 10.1016/S0169-5002(01)00239-2

Hotta, 2004, Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small cell lung cancer, J Clin Oncol, 22, 3852, 10.1200/JCO.2004.02.109

Sculier, 2007, Bevacizumab for non-small cell lung cancer, N Engl J Med, 356, 1373, 10.1056/NEJMc070042

Robinson, 2002, Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed, Int J Epidemiol, 31, 150, 10.1093/ije/31.1.150

Jadad, 1996, Assessing the quality of reports of randomized clinical trials: is blinding necessary?, Control Clin Trials, 17, 1, 10.1016/0197-2456(95)00134-4

M Egger, 2005

Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629

Smit, 2003, Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975, J Clin Oncol, 21, 3909, 10.1200/JCO.2003.03.195

Bucher, 1997, The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials, J Clin Epidemiol, 50, 683, 10.1016/S0895-4356(97)00049-8

Alberola, 2003, Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial, J Clin Oncol, 21, 3207, 10.1200/JCO.2003.12.038

Chen, 2002, Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated, Ann Oncol, 13, 108, 10.1093/annonc/mdf009

Georgoulias, 2005, Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial, J Clin Oncol, 23, 2937, 10.1200/JCO.2005.04.016

Georgoulias, 2001, Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial, Lancet, 357, 1478, 10.1016/S0140-6736(00)04644-4

Georgoulias, 2001, Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial, Lung Cancer, 34, S47, 10.1016/S0169-5002(01)00417-2

Gridelli, 2003, J Clin Oncol, 21, 3025, 10.1200/JCO.2003.06.099

Kosmidis, 2002, Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial, J Clin Oncol, 20, 3578, 10.1200/JCO.2002.12.112

Lilenbaum, 2005, Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer, Ann Oncol, 16, 97, 10.1093/annonc/mdi009

Mok, 2005, Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer, Oncology, 68, 485, 10.1159/000086992

Pujol, 2005, Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin, Ann Oncol, 16, 602, 10.1093/annonc/mdi126

Stathopoulos, 2004, Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial, Ann Oncol, 15, 1048, 10.1093/annonc/mdh260

Tan, 2005, Randomized study of vinorelbine—gemcitabine versus vinorelbine—carboplatin in patients with advanced non-small-cell lung cancer, Lung Cancer, 49, 233, 10.1016/j.lungcan.2005.03.029

Wachters, 2003, First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial, Br J Cancer, 89, 1192, 10.1038/sj.bjc.6601283

Yamamoto, 2004, Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803), Br J Cancer, 90, 87, 10.1038/sj.bjc.6601462

Yamamoto, 2006, Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced non-small-cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104, Cancer, 107, 599, 10.1002/cncr.22024

Barata, 2002, A phase II study, multicenter, randomized of carboplatin plus gemcitabine (CG) versus vinorelbine plus gemcitabine (VG) in advanced non-small-cell lung cancer (NSCLC), Lung Cancer, 13

Ardizzoni, 2006, CISCA (cisplatin vs. carboplatin) meta-analysis: an individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer (NSCLC), J Clin Oncol, 24, 7011, 10.1200/jco.2006.24.18_suppl.7011

Go, 1999, Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin, J Clin Oncol, 17, 409, 10.1200/JCO.1999.17.1.409

Juni, 2001, Systematic reviews in health care: assessing the quality of controlled clinical trials, BMJ, 323, 42, 10.1136/bmj.323.7303.42